AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
63.20
-0.60 (-0.94%)
At close: Nov 20, 2024, 4:00 PM
63.74
+0.54 (0.85%)
Pre-market: Nov 21, 2024, 5:47 AM EST
AstraZeneca Employees
AstraZeneca had 89,900 employees as of December 31, 2023. The number of employees increased by 6,400 or 7.66% compared to the previous year.
Employees
89,900
Change (1Y)
6,400
Growth (1Y)
7.66%
Revenue / Employee
$569,588
Profits / Employee
$72,247
Market Cap
195.32B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
Dec 31, 2013 | 51,500 | -200 | -0.39% |
Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
Dec 31, 2007 | 67,400 | 600 | 0.90% |
Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Danaher | 63,000 |
AbbVie | 50,000 |
Amgen | 26,700 |
AZN News
- 1 day ago - AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US - Business Wire
- 2 days ago - GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study - PRNewsWire
- 2 days ago - Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC - PRNewsWire
- 5 days ago - Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head - Investopedia
- 5 days ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 6 days ago - Pharma shares hit as Trump picks RFK Jr to lead health department - The Guardian
- 7 days ago - AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity - Seeking Alpha
- 7 days ago - Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy - CNBC